<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798173</url>
  </required_header>
  <id_info>
    <org_study_id>HILLON HORS AOI 2008</org_study_id>
    <nct_id>NCT01798173</nct_id>
  </id_info>
  <brief_title>Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients</brief_title>
  <acronym>CIRCE</acronym>
  <official_title>CIRCE: Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      Available data do not allow carcinogenesis mechanisms in cirrhotic patients to be well
      understood in absence of studies taking into account all recognised factors. A large scale
      clinical, biochemical and molecular studies is potentially relevant to the understanding of
      nutrition, physical activity, body weight metabolic syndrome whatever the etiology of
      underlying cirrhosis. It will open new perspectives :

        -  in prevention of hepatocellular carcinoma development in cirrhotic patients through
           dietary counselling and therapeutics of metabolic syndrome,

        -  in early screening of hepatocellular carcinoma in cirrhotic patients through
           spectroscopic technology and later proteomic study resulting in an improvement of
           hepatocellular carcinoma prognosis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosage of the vitamin B12 and the folates</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Cirrhosis With Hepatocellular Carcinoma</condition>
  <condition>Cirrhosis Without Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cases: cirrhotic patients with hepatocellular carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls: cirrhotic patients without hepatocellular carcinoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Serum, plasma and DNA samples</intervention_name>
    <arm_group_label>Cases: cirrhotic patients with hepatocellular carcinoma</arm_group_label>
    <arm_group_label>Controls: cirrhotic patients without hepatocellular carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiological exploration by CT scan or MRI</intervention_name>
    <arm_group_label>Cases: cirrhotic patients with hepatocellular carcinoma</arm_group_label>
    <arm_group_label>Controls: cirrhotic patients without hepatocellular carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cases and controls will be males and females aged 35 or older, and will give an informed
        consent to participate in the study.

        * Hepatocellular carcinoma case:

        All hepatocellular carcinoma cases evolving in cirrhotic liver, whatever the etiology of
        cirrhosis, will be included. Criteria for the diagnosis of hepatocellular carcinoma will be
        those defined by the European Association for Study of the Liver (EASL) (Bruix J, J Hepatol
        2001):

        Focal hepatic lesions ≥ 2cm in diameter:

          -  alpha-fetoprotein (AFP) &lt; 400 ng/ml: nodules have to be identified by at least two
             coincident morphologic examinations (abdominal US, angiography, CT or MRI) with
             arterial hypervascularisation in at least one of the imaging modalities

          -  AFP &gt; 400 ng/ml: lesion seen in a single imaging modality

        Focal hepatic lesions &lt; 2 cm in diameter:

          -  lesions 1 to 2 cm in diameter:use of fine-needle aspiration with biopsy

          -  lesions &lt; 1 cm: serial abdominal US every 3 months until the lesion exceeds 1 cm in
             size so that biopsy becomes possible. Such cases will be included after diagnosis
             confirmation.

        Whatever the size of focal lesions, the diagnosis of cirrhosis will be made according to
        the same criteria as in the cirrhotic group control.

        * Cirrhotic control patients:

        All patients with cirrhosis, whatever its etiology, will be included. The diagnosis of
        cirrhosis will rely on:

        Histological confirmation by liver biopsy or in the absence of biopsy:

          -  in patients free of portal thrombosis at Doppler imaging, on the presence of portal
             hypertension ascertained by biological (tricytopenia), morphologic (abdominal US, CT
             or MRI), hepatic venous pressure measurement or upper endoscopy (mosaic gastropathy,
             varices).

          -  in patients with portal thrombosis, on the presence of portal hypertension associated
             with: Clinical (hepatomegaly with clinical evidence of hepatocellular failure: spider
             naevi, palmar erythema, white mails, gynecomastia) or morphological signs of cirrhosis
             (enlarged liver, nodular surface, sharp lower edge).

        And/or biological signs of hepatocellular failure (TP&lt;70%, low albuminemia) And/or
        sinusoidal block assessed by liver venous gradient &gt; 18mmHG In the present state of
        knowledge, a fibrotest value at 4 or a fibroscan value &gt; 12.5 kilopascal.

        Without any other clinical or biological signs will be considered as diagnosis criteria of
        cirrhosis only for chronic viral C hepatitis.

        The lack of hepatocellular carcinoma in cirrhotic patients at inclusion will be assessed
        through good quality imaging examinations (abdominal US, CT scan or MRI) and AFP below 100
        ng/ml.

        Exclusion Criteria:

          -  age under 35 of year

          -  other cancer in evolution

          -  HIV infection

          -  Major somatic pr psychiatric illness not compatible with the inclusion in the study

          -  No hepatocellular carcinoma primary liver cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick HILLON</last_name>
    <phone>3 80 29 37 50</phone>
    <phone_ext>+33</phone_ext>
    <email>patrick.hillon@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carine RICHOU</last_name>
      <phone>3 81 66 84 21</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Carine RICHOU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Paul CERVONI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent DI MARTINO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry THEVENOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Louis JOUVE</last_name>
      <phone>3 80 29 37 50</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Jean-Louis JOUVE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent BEDENNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean FAIVRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick HILLON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Come LEPAGE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne MINELLO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice GAGNAIRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boris GUIU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de METZ</name>
      <address>
        <city>Metz</city>
        <zip>57038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Jacques RAABE</last_name>
      <phone>3 87 55 33 50</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Jean-Jacques RAABE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte LE GUILLOU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Robert DEBRE</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard THIEFFIN</last_name>
      <phone>3 26 78 37 65</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Gérard THIEFFIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier BOUCHE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra HEURGUE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brigitte BERNARD CHABERT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie LAGARDE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude BERTIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie SCAGLIA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florent EHRHARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique médicale B. Hôpital Civil-Hôpitaux Universitaires</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de BRABOIS</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2013</study_first_submitted>
  <study_first_submitted_qc>February 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2013</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Environmental risk factors</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

